Inflammatory Biomarkers in Patients with Parkinson's Disease: Correlations with Clinical Severity and Levodopa Therapy

[摘要] Background: There is increasing recognition of the possible role of neuroinflammation as a major factor in the pathogenesis of PD. Objective: This case-control study was designed to measure serum levels of anti-inflammatory cytokine (IL10), pro-inflammatory cytokine (IL15) as well as chemokines (RANTES) in patients with PD and to assess their correlations with clinical presentation as well as the effect of levodopa therapy. Methods: Thirty patients affected by idiopathic PD [group I] were selected from Outpatients Neurology Clinics, Zagazig University Hospitals. Twenty healthy age- and sex-matched subjects were chosen as a control group [group II]. Parkinsonian disability was measured by motor subscale of the Unified Parkinson' Disease Rating Scale (UPDRS), Hoehn and Yahr (HY) stage; and Schwab and England scale. Determination of serum IL10, IL15 and RANTES were done to both patients and control group. Results: The PD group, in our work, presented with significantly increased IL15 and RANTES levels and non significantly elevated IL10 levels as compared to the control group. There were significant relations between IL10, an immunosuppressive cytokine and IL15, proinflammatory cytokine in PD patients. We found also that PD patients with L-DOPA therapy had non significantly elevation of serum levels of IL15 and RANTES compared to non treated patients. There were significant correlation between IL10 and RANTES serum levels and motor component of UPDRS. Conclusion: Central or systemic inflammation should be considered a risk factor for PD and should be efficiently handled or prevented in patients with PD to reduce exacerbated disease progression. [Egypt J Neurol Psychiat Neurosurg.  2011; 48(2): 111-116]

[学科分类] 精神健康和精神病学